
How Ozempic's maker lost its grip on the obesity market it created
Today, the Danish company has lost its grip on the anti-obesity market it carved out.
The company has lost market share amid production missteps and a bungled rollout of Wegovy that led to shortages. Its U.S. rival Eli Lilly—initially in the rearview mirror—has been proven to have the more effective weight-loss drug and a more promising pipeline of next-generation treatments. Novo Nordisk's research-and-development machine has disappointed, and a key marketing strategy was slow to get off the ground.
Novo Nordisk's ability to stay atop a market that analysts see growing to $150 billion in annual sales is now in doubt. Its controlling shareholder this month forced a surprise ouster of the company's chief executive, Lars Fruergaard Jørgensen. And while it is still generating multibillion-dollar sales for Ozempic and Wegovy, shares have tumbled more than 50% over the past year.
If Novo Nordisk doesn't turn things around, it could join a long list of companies that blew a first-mover advantage, from Sunshine Biscuits—whose Hydrox cookies were overtaken by now-iconic Oreos—to the Myspace social network.
'Everyone wants to be the first footprints on the empty beach," said Americus Reed, marketing professor at the Wharton School of the University of Pennsylvania. 'But it depends on how you land on that first move. The second mover is watching them make mistakes. You're able to identify those and not make those mistakes."
Lars Fruergaard Jørgensen, who was pushed out as CEO of Novo Nordisk earlier this month.Novo Nordisk lost market share after miscalculating demand in the launch of weight-loss drug Wegovy.
A Novo Nordisk spokeswoman said the company remains the global-volume market leader in GLP-1 drugs, serving nearly two-thirds of patients taking them for diabetes and obesity.
Some investors and industry watchers say Novo Nordisk's troubles stem from a cautious, reactive approach starting when the market first burst onto the scene, in contrast with a faster, more aggressive tack in production and marketing by Lilly.
'Novo is always a step behind," said Yuri Khodjamirian, chief investment officer at Tema ETFs, which owns Novo Nordisk shares.
One of Novo Nordisk's early stumbles was underestimating the demand for Wegovy—the weight-loss version of semaglutide, the same compound as diabetes drug Ozempic—ahead of its 2021 launch. The company's planning was informed by its experience generating modest sales for an earlier weight-loss drug, Saxenda. Doctors were skeptical of it, and many health-insurance plans in the U.S. didn't cover weight-loss drugs.
Novo Nordisk thought Wegovy might run into the same market constraints as Saxenda, so the company planned modest production levels, using a combination of in-house and contract manufacturing capacity.
It wasn't enough. It took only five weeks for the prescription rate of Wegovy to exceed the level that Saxenda had taken five years to reach. Jørgensen recalled later, in an interview in 2024, that he initially thought: ''That's patients who've been lined up, there's pent-up demand, it will normalize.' It didn't. It just kept growing."
The company responded by limiting demand—the last thing a drugmaker wants to do with a new product. Sales representatives asked doctors not to start new patients. The company resorted to rationing by withholding the lower, starter doses for new patients, to conserve supplies for existing patients taking the higher doses.
The shortages opened the door for competition. They made it legal for special pharmacies in the U.S. to make compounded, copycat versions of semaglutide that sold for much less than list prices for Ozempic and Wegovy. Telehealth firms capitalized on the new, lower-cost supply by hawking the compounded versions, taking away market share from Novo Nordisk.
Eli Lilly activated a manufacturing plant in Concord, N.C., to keep up with a surge in demand for Mounjaro and Zepbound.
The shortages gave rival Eli Lilly time to catch up. Lilly introduced Mounjaro for diabetes in 2022, followed by Zepbound, a weight-loss version of the same drug, in 2023. Zepbound has been shown in studies to induce greater weight loss than Wegovy, more than 20% of body weight.
Although Lilly also encountered shortages due to high demand, it was able to resolve them more quickly than Novo Nordisk. Now, weekly U.S. prescriptions for Lilly's Zepbound have surpassed Wegovy's. Mounjaro still trails Ozempic but is closing the gap.
Novo Nordisk has spent billions of dollars trying to expand manufacturing capacity, including an unusual deal last year for its controlling foundation to acquire the contract manufacturer Catalent for $16 billion.
The R&D race for future weight-loss drugs also has tilted in Eli Lilly's direction. Lilly has reported favorable clinical-trial data for two closely watched experimental drugs, including a pill version that analysts think could be appealing to people who don't want injections.
Novo Nordisk, meanwhile, has had some R&D disappointments, including studies of an experimental combination weight-loss drug dubbed CagriSema. The less-than-expected results of one study sent Novo Nordisk shares plunging more than 20% in one day in December, wiping out nearly $100 billion in stock-market capitalization for the company. Some analysts have cut their sales forecasts for the drug.
Novo Nordisk's Wegovy has been surpassed in weekly U.S. prescriptions by Lilly's Zepbound.
Lilly has gained an edge on the marketing front as well. The company beat Novo Nordisk to the punch in launching a direct-to-consumer, online service selling weight-loss drugs at discounted cash prices, aimed at people who don't have insurance coverage. And it was first to strike a deal with a big telehealth firm, Ro, to sell a discounted weight-loss drug. Novo Nordisk eventually made similar moves, but months after Lilly.
'They seem to be missing a lot of these kinds of strategic endeavors to help sell into a market that is different from a lot of pharma markets," said BMO Capital Markets analyst Evan David Seigerman.
The Novo Nordisk spokeswoman said the company resolved its shortages before announcing its direct-to-patient service and striking telehealth deals.
Novo Nordisk isn't out of the race. The company can still turn things around by leaning into CagriSema, which generated solid weight-loss data even if it missed expectations, and by developing other new drugs that target various segments of the growing market, Seigerman said.
More recently, Novo Nordisk has shown signs of being more aggressive. It signed a deal with CVS to make Wegovy the preferred weight-loss drug for members of its drug-benefit plans.
Author Hanne Sindbæk, who has written two books about Novo Nordisk, says there has been an eternal tug of war inside the company between those who are guided by values—the idea that the company works for the common good rather than simply to make a profit—and those who run the business. If Novo Nordisk wants to stay in the game, it may have to lean toward the latter in choosing its next CEO.
Jørgensen, the outgoing CEO, is still in his role while the company searches for a new chief. His predecessor as CEO, Lars Rebien Sørensen, who is chairman of the foundation that has voting control of the drugmaker's shares, will join the Novo Nordisk board of directors.
'Now they need somebody more business-driven," Sindbæk said.
Write to Peter Loftus at Peter.Loftus@wsj.com and Noemie Bisserbe at noemie.bisserbe@wsj.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fibre2Fashion
4 hours ago
- Fibre2Fashion
France's LVMH holds strong in Europe; H1 sales down to $46.96 bn
French luxury brand LVMH Moet Hennessy Louis Vuitton has reported a revenue of €39.8 billion (~$46.96 billion) in the first half (H1) of 2025, down 4 per cent from €41.7 billion in H1 2024. Despite challenging geopolitical and economic conditions, the group demonstrated resilience, bolstered by robust local demand in Europe and the United States. The profit from recurring operations declined 15 per cent year-over-year (YoY) to €9 billion, representing an operating margin of 22.6 per cent. The net profit attributable to the group stood at €5.7 billion (~$6.67 billion), down 22 per cent. Operating free cash flow rose significantly by 29 per cent to €4 billion, while net financial debt decreased by 16 per cent to €10.2 billion. LVMH has reported a revenue of €39.8 billion (~$46.96 billion) in H1 2025, down 4 per cent YoY, with net profit falling 22 per cent to €5.7 billion (~$6.67 billion). Fashion and Leather Goods led with €19.1 billion (~$22.538 billion) revenue, despite reduced tourist spending. Q2 saw a sequential dip in this segment. Strong local demand in Europe and the US supported resilience. Segment-wise, Fashion & Leather Goods, LVMH's largest division, recorded a revenue decline of 8 per cent to €19.1 billion (~$22.54 billion), with operating profit falling 18 per cent to €6.6 billion. Despite reduced tourist spending, local demand remained resilient, with strong performances by Louis Vuitton, Dior, Fendi, and Loewe. Region-wise, Europe and the United States saw solid local demand. Japan reported a decline due to the extraordinary tourist boost in H1 2024. Asia (ex-Japan) remained stable, with improving local sales in Q2 2025. Selective Retailing achieved 2 per cent organic growth, maintaining revenue at €8.6 billion and improving operating profit by 12 per cent to €876 million. In the second quarter (Q2) of 2025, LVMH reported a revenue of €9,006 million in Fashion and Leather Goods division. This marks a sequential decline from €10,108 million recorded in Q1 2025, reflecting the ongoing impact of a disrupted geopolitical environment and normalisation in tourist spending, particularly in Japan. 'LVMH showed solidity in the current context. We owe this to the power of our iconic brands and their boundless capacity for innovation while remaining true to their culture of incomparable artisanal craftsmanship. Beyond the prevailing uncertainties, we remain focused thanks to the long-term vision that has always guided our family group,' said Bernard Arnault, chairman and chief executive officer (CEO) at LVMH. 'We are driven by our steadfast pursuit of quality and desirability in everything we create, combined with the modernity of our historic brands. We head into the second half of the year with great vigilance, and I am confident in LVMH's tremendous long-term potential and the commitment of our teams to further reinforce the Group's leadership position in luxury goods. Our main shared priority is about offering our customers the most exceptional products,' added Arnault. LVMH remains cautious heading into the second half (H2) of 2025 but reaffirmed its long-term strategy centred on brand desirability, craftsmanship, and retail excellence. Fibre2Fashion News Desk (SG)


Hindustan Times
9 hours ago
- Hindustan Times
Orthopedic surgeon explains 'best way to loose belly fat without side effects'
Green tea extract is often cited as a potential aid for weight loss due to its high concentration of catechins, particularly epigallocatechin gallate. On June 26, Dr Manu Bora, an orthopedic surgeon, took to Instagram to share how it can contribute to weight loss. Also read | 7 weight loss myths busted by celebrity fitness trainer Tridev Pandey: 'Never go for Ozempic…' Green tea extract contains catechins, which can increase metabolism and enhance fat burning.(Shutterstock) Why do you need green tea extract? In the video he posted, Dr Bora said, 'What is the way to lose belly fat without any side effects? When we talk about fat-burners or weight loss, we usually mean exercise. If you exercise a lot, you will lose weight. It is very difficult to lose weight, and there are many drugs on the market. There are many fat burners, and there are caffeine fat-burners. So, which is the safest out of all? There is one such drug that is a very powerful antioxidant. It also has a fat burner. It will keep many diseases away from your body. Antioxidant means that as our body gets inflamed, oxidative stress increases. Stress, pollution, bad food, sugar, oil – all of these cause oxidative stress and fat to increase. If there is a powerful antioxidant, it will reverse it, so that your body does not age. Ageing means no glycation, no wrinkles, no stress. Your body will be healthy, will stay away from diseases, and it will also work for fat burning.' He added, 'So that product is called green tea extract. Just remember one thing – don't take it during pregnancy and don't take it with small children. Second, don't take it before going to bed. So you can take it twice a day, in the morning and afternoon. But try not to take after evening, before night because you will have trouble sleeping. But it will cause weight loss very quickly with exercise. It will cause weight loss in a natural way. The side-effects are very less. The beneficial effects are very high. It detoxifies everything. Along with this, it is important to exercise.' More details In a 2023 article, shared '10 science-based benefits of green tea extract' and said that many studies have looked at the ability of green tea extract to aid weight loss. In fact, many weight loss products list it as a key ingredient. Despite these benefits, it's important to know that green tea extract can also be toxic when taken in excess, so always talk with a health professional if you're interested in taking these supplements, the report said. Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.


The Hindu
a day ago
- The Hindu
Lupin gets U.S. FDA nod for two generic diabetes drugs
Generic drugmaker Lupin has received U.S. Food and Drug Administration approval for its abbreviated new drug applications for Liraglutide Injection single-patient-use prefilled pens and Glucagon for injection vials. Both the products will be manufactured at the company's injectable facility in Nagpur, Lupin said. Liraglutide injection 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pen is bioequivalent to Novo Nordisk's Victoza injection and had an estimated annual sale of $458 million in the U.S, the company said citing IQVIA MAT May numbers. The drug is indicated to improve glycaemic control in adults and children, aged above 10 years, with type 2 diabetes mellitus. Glucagon for Injection USP, 1 mg/vial, is bioequivalent to Eli Lilly and Company's Glucagon for Injection, 1 mg/vial. It is indicated for treatment of severe hypoglycaemia in paediatric and adult patients with diabetes mellitus and as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients. It had an estimated annual sale of $124 million in the U.S. Chief Scientific Officer Shahin Fesharaki said the two products are a meaningful enhancement to the company's portfolio.